Morgan Stanley upgraded Afya from Equal-Weight to Overweight and set a new price target of $20.50 from $16.50 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2024 | $19.50 | Neutral | UBS |
| 1/29/2024 | $23.00 | Neutral | Citigroup |
| 1/22/2024 | $20.50 → $23.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/13/2023 | $16.50 → $20.50 | Equal-Weight → Overweight | Morgan Stanley |
| 4/8/2022 | $18.00 → $19.00 | Neutral → Outperform | Credit Suisse |
| 3/7/2022 | $27.00 → $21.00 | Buy | UBS |
| 7/21/2021 | $28.50 | Overweight → Equal-Weight | Morgan Stanley |
SCHEDULE 13G - Afya Ltd (0001771007) (Subject)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
UBS initiated coverage of Afya with a rating of Neutral and set a new price target of $19.50
Citigroup initiated coverage of Afya with a rating of Neutral and set a new price target of $23.00
Morgan Stanley downgraded Afya from Overweight to Equal-Weight and set a new price target of $23.00 from $20.50 previously
Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Expressive Cash Generation Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and nine-month periods ended September 30, 2024 (third quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2024 Highlights 3Q24 Net Revenue increased 16.3% YoY to R$841.2 million. Net Revenue excluding acquisitions grew 11.8%, reaching R$808.8 million. 3Q24 Ad
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that it will report third-quarter and nine months 2024 financial results for the period ended September 30th, 2024, following the close of the market on Wednesday, November 13th, 2024 and will host a corresponding conference call and webcast at 05:00 pm EST. A live and archived webcast of the call will be available on the Investor Relations section of the Company's website at: https://ir.afya.com.br/financials/quarterly-earnings/ To participate in Afya's Third Quarter and Nine Months 2024 conference call, please follow
Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, today announced that it will host its Afya Day on October 29th, 2024. The event will be held in a hybrid format, combining both in-person and online participation, and will feature presentations from Afya's executive team, covering the Company's growth, business strategy and future outlook. Event Details: Date: October 29th, 2024. Time: 9:00 a.m. to 12:00 p.m. (São Paulo time) & 8:00 a.m. to 11:00 a.m. (EST). Format: Hybrid (in-person and virtual participation) Location for in-person attendees: Afya's São Paulo Flagship, Alameda Lore
NOVA LIMA, Brazil and MINAS GERAIS, Brazil, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA), today announces that its clinical decision software, WhiteBook, an app created by PEBMED, was ranked as one of the 10 Top Apps in Brazil by consumer spend in 2020 for the fifth year in a row. App Annie conducted the study, a website specialized in app analytics and app market data that combined data from iOS and Google Play that evaluates more than 8 million mobile app per year. In the top ten WhiteBook was among great apps such as Tinder, YouTube, Netflix, TikTok and others. Whitebook is a mobile and web application software that helps doctors and medical students to make
Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Expressive Cash Generation Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and nine-month periods ended September 30, 2024 (third quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2024 Highlights 3Q24 Net Revenue increased 16.3% YoY to R$841.2 million. Net Revenue excluding acquisitions grew 11.8%, reaching R$808.8 million. 3Q24 Ad
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that it will report third-quarter and nine months 2024 financial results for the period ended September 30th, 2024, following the close of the market on Wednesday, November 13th, 2024 and will host a corresponding conference call and webcast at 05:00 pm EST. A live and archived webcast of the call will be available on the Investor Relations section of the Company's website at: https://ir.afya.com.br/financials/quarterly-earnings/ To participate in Afya's Third Quarter and Nine Months 2024 conference call, please follow
Solid Organic Growth Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and six-month period, which ended on June 30, 2024 (second quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second Quarter 2024 Highlights 2Q24 Net Revenue increased 13.7% YoY to R$809.9 million. 2Q24 Adjusted EBITDA increased 28.2% YoY reaching R$343.8 million, with an Adjus
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
Morgan Stanley analyst Mauricio Cepeda maintains Afya (NASDAQ:AFYA) with a Equal-Weight and lowers the price target from $21 to $19.
Afya (NASDAQ:AFYA) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.45 by 22.22 percent. This is a 61.76 percent increase over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $162.47 million which beat the analyst consensus estimate of $156.68 million by 3.70 percent. This is a 18.90 percent increase over sales of $136.65 million the same period last year.
Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and digital health services provider in Brazil, announced today that it has entered into a share purchase agreement for the acquisition, through its wholly-owned subsidiary Afya Participações S.A., of 100% of the total share capital of Unidom Participações S.A. ("Unidompedro" and "Faculdade Dom Luiz"), present in Salvador (BA), Luis Eduardo Magalhães (BA), Barreiras (BA) and Ribeira do Pombal (BA).The acquisition will add 300 operational medical school seats to Afya in Salvador, one of Brazil's largest cities. The authorization request for these 300 seats was made to the Ministry of Educat